<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03940066</url>
  </required_header>
  <id_info>
    <org_study_id>Monitor- ACS - EPIC 013</org_study_id>
    <nct_id>NCT03940066</nct_id>
  </id_info>
  <brief_title>Evaluation of Ambulatory Monitoring of Patients After High-risk Acute Coronary Syndrome Using Two Different Systems: Biomonitor-2 and Kardia Mobile</brief_title>
  <acronym>Monitor- ACS</acronym>
  <official_title>Evaluation of Ambulatory Monitoring of Patients After High-risk Acute Coronary Syndrome Using Two Different Systems: Biomonitor-2 and Kardia Mobile</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación EPIC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación EPIC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the efficacy of monitoring after discharge of
      patients with high-risk acute coronary syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the study is to evaluate the efficacy of monitoring after discharge of
      patients with high-risk acute coronary syndrome.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 12, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Atrial fibrilation (AF / atrial flutter)</measure>
    <time_frame>1 year</time_frame>
    <description>Detection rates for atrial fibrilation (AF / atrial flutter) during the follow up.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ventricular arrhythmia in the electrocardiogram (EKG)</measure>
    <time_frame>1 year</time_frame>
    <description>Detection rates of ventricular arrhythmia in the electrocardiogram (EKG) during the follow up.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Advanced conduction abnormalities and significant ST shifts (&gt; 1 mm) in the EKG</measure>
    <time_frame>1 year</time_frame>
    <description>Detection rates of advanced conduction abnormalities and significant ST shifts (&gt; 1 mm) in the EKG.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)</measure>
    <time_frame>1 year</time_frame>
    <description>MACCE rates defined as cardiovascular and cerebrovascular events during the follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-hospitalization</measure>
    <time_frame>1 year</time_frame>
    <description>Number of Re-hospitalization during the follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of primary outcomes between Biomonitor-2 versus Kardia Mobile</measure>
    <time_frame>1 year</time_frame>
    <description>Correlation of primary outcomes between Biomonitor-2 versus Kardia Mobile during the follow up.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Syncope</condition>
  <condition>Tachycardia</condition>
  <condition>Arrhythmias, Cardiac</condition>
  <condition>Heart Diseases</condition>
  <arm_group>
    <arm_group_label>Monitoring group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Biomonitor-2 and Kardia mobile</intervention_name>
    <description>Implantable cardiac monitor and Smart-phone based electrocardiogram recording</description>
    <arm_group_label>Monitoring group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Intervention</intervention_name>
    <description>No intervention</description>
    <arm_group_label>Standard Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is able to understand the nature of study and has provided written informed
             consent.

          -  Patient with Acute Coronary Syndrome, with or without elevation of the ST segment at
             the EKG (the last with elevation of troponins).

          -  Patient with coronariography at the episode of ACS showing severe lesions treated with
             stent.

          -  Patient with risk index for 6-month mortality (GRACE score) of more than 118.

          -  Patient with risk index for stroke (CHA2DS2-VACS score) of more than 2.

        Exclusion Criteria:

          -  Patient with history of AF.

          -  Patient with episodes of AF during admission at the current episode.

          -  Patient with pacemaker or ICD (implantable cardioverter-defibrillator) previously.

          -  Patient with indication of pacemaker or ICD in current or short-term phase.

          -  Patient is participating in another interventional clinical investigation.

          -  Patient is pregnant or breast feeding.

          -  Patient´s life-expectancy is less than 24 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Felipe Rodríguez Entem, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Marqués de Valdecilla</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José M De la Torre Hernández, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Marqués de Valdecilla</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>José M De la Torre Hernández, MD, PhD</last_name>
    <phone>+34987876135</phone>
    <email>jmdelatorre@fundacionepic.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fundación EPIC</last_name>
    <phone>+34987876135</phone>
    <email>iepic@fundacionepic.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J. 2015 May 14;36(19):1163-70. doi: 10.1093/eurheartj/ehu505. Epub 2015 Jan 13.</citation>
    <PMID>25586123</PMID>
  </reference>
  <reference>
    <citation>Bhatt DL, Eagle KA, Ohman EM, Hirsch AT, Goto S, Mahoney EM, Wilson PW, Alberts MJ, D'Agostino R, Liau CS, Mas JL, Röther J, Smith SC Jr, Salette G, Contant CF, Massaro JM, Steg PG; REACH Registry Investigators. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010 Sep 22;304(12):1350-7. doi: 10.1001/jama.2010.1322. Epub 2010 Aug 30.</citation>
    <PMID>20805624</PMID>
  </reference>
  <reference>
    <citation>Eagle KA, Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, Van de Werf F, Goodman SG, Granger CB, Steg PG, Gore JM, Budaj A, Avezum A, Flather MD, Fox KA; GRACE Investigators. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA. 2004 Jun 9;291(22):2727-33.</citation>
    <PMID>15187054</PMID>
  </reference>
  <reference>
    <citation>Chua SK, Lo HM, Chiu CZ, Shyu KG. Use of CHADS₂ and CHA₂DS₂-VASc scores to predict subsequent myocardial infarction, stroke, and death in patients with acute coronary syndrome: data from Taiwan acute coronary syndrome full spectrum registry. PLoS One. 2014 Oct 24;9(10):e111167. doi: 10.1371/journal.pone.0111167. eCollection 2014.</citation>
    <PMID>25343586</PMID>
  </reference>
  <reference>
    <citation>Halcox JPJ, Wareham K. Response by Halcox and Wareham to Letter Regarding Article, &quot;Assessment of Remote Heart Rhythm Sampling Using the AliveCor Heart Monitor to Screen for Atrial Fibrillation: The REHEARSE-AF Study&quot;. Circulation. 2018 May 15;137(20):2193-2194. doi: 10.1161/CIRCULATIONAHA.118.033773.</citation>
    <PMID>29760234</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>May 5, 2019</study_first_submitted>
  <study_first_submitted_qc>May 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2019</study_first_posted>
  <last_update_submitted>November 15, 2019</last_update_submitted>
  <last_update_submitted_qc>November 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiac Monitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syncope</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

